Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Next Previous
Search
Trial Profile

Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications B-cell lymphoma; Cutaneous B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 13 Dec 2022 Results(n=17) assessing safety and efficacy of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 04 May 2021 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.
  • 04 May 2021 Planned primary completion date changed from 1 Jun 2021 to 22 Oct 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top